Orum Doses First Patient with ORM-1153

Company Orum Therapeutics Event Type First Patient Dosed (Phase 1) Modality Degrader-antibody conjugate (GSPT1 molecular-glue degrader payload) Asset ORM-1153 Target CD123 (antibody); GSPT1 (payload) Disease Area Relapsed or refractory AML and other CD123-positive hematologic malignancies Summary Orum Therapeutics dosed the first patient in a Phase…